Safety and Tolerability of More than Six Days of Tedizolid Treatment.


Por: Mensa Vendrell M, Tasias Pitarch M, Salavert Lletí M, Calabuig Muñoz E, Morata Ruiz L, Castells Lao G, López Suñé E, Mensa Pueyo J, Oltra Sempere MR, Pedro-Botet Montoya ML, Isernia V, Reynaga Sosa EA, Moreno Nuñez L, Pasquau Liaño J, Sequera Arquelladas S, Yuste Ara JR and Soriano Viladomiu A

Publicada: 23 jun 2020 Ahead of Print: 23 jun 2020
Resumen:
Tedizolid has demonstrated its efficacy and safety in clinical trials; however, data concerning its tolerability in long-term treatments are scarce. The aim of the study was to assess the indications and to describe the long-term safety profile of tedizolid. A multicentric retrospective study of patients who received tedizolid for more than 6 days was conducted. Adverse events (AEs) were identified from patients' medical records and laboratory data. The World Health Organization causality categories were used to discern AEs that were probably associated with tedizolid. Eighty-one patients, treated with tedizolid 200 mg once daily for a median (interquartile range [IQR]) duration of 28 (14 to 59) days, were included; 36 (44.4%) had previously received linezolid. The most common reasons for selecting tedizolid were to avoid linezolid potential toxicities or interactions (53.1%) or due to previous linezolid-related toxicities (27.2%). The most common indications were off-label, including prosthetic joint infections, osteomyelitis, and respiratory infections (77.8%). Overall, 9/81 patients (11.1%) experienced a probably associated AE. Two patients (2.5%) developed gastrointestinal disorders, 1 (1.2%) developed anemia, and 6 developed thrombocytopenia (7.4%) after a median (IQR) duration of treatment of 26.5 (17 to 58.5) days. Four (5%) patients discontinued tedizolid due to AEs. Among 23 patients with chronic renal failure (CRF), the rate of myelotoxicity was 17.4%, and only 8.7% had to stop tedizolid; 20 out of 22 with previous linezolid-associated toxicity had no AE. Long-term tedizolid treatments had good tolerance with rates of gastrointestinal AE and hematological toxicity lower than those reported with linezolid, particularly in patients with CRF and in those with a history of linezolid-associated toxicity.

Filiaciones:
Mensa Vendrell M:
 Pharmacy Department, Hospital Plató, Barcelona, Spain

Tasias Pitarch M:
 Department of Infectious Diseases, Hospital Universitario y Politécnico La Fe, Valencia, Spain

Salavert Lletí M:
 Department of Infectious Diseases, Hospital Universitario y Politécnico La Fe, Valencia, Spain

Calabuig Muñoz E:
 Department of Infectious Diseases, Hospital Universitario y Politécnico La Fe, Valencia, Spain

Morata Ruiz L:
 Department of Infectious Diseases, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain

Castells Lao G:
 Pharmacy Department, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain

López Suñé E:
 Pharmacy Department, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain

Mensa Pueyo J:
 Department of Infectious Diseases, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain

Oltra Sempere MR:
 Department of Infectious Diseases, Hospital Clínico Universitario de València, Valencia, Spain

:
 Department of Infectious Diseases, Hospital Germans Trias i Pujol, Barcelona, Spain

Isernia V:
 Department of Infectious Diseases, Hospital Germans Trias i Pujol, Barcelona, Spain

Reynaga Sosa EA:
 Department of Infectious Diseases, Hospital Germans Trias i Pujol, Barcelona, Spain

Moreno Nuñez L:
 Department of Infectious Diseases, Hospital Universitario Fundación Alcorcón, Madrid, Spain

Pasquau Liaño J:
 Department of Infectious Diseases, Hospital Universitario Virgen de las Nieves de Granada, Granada, Spain

Sequera Arquelladas S:
 Department of Infectious Diseases, Hospital Universitario Virgen de las Nieves de Granada, Granada, Spain

Yuste Ara JR:
 Department of Infectious Diseases, Clínica Universidad de Navarra, Navarra, Spain
ISSN: 00664804





Antimicrobial Agents And Chemotherapy
Editorial
American Society for Microbiology, 1752 N ST NW, WASHINGTON, DC 20036-2904 USA, Estados Unidos America
Tipo de documento: Article
Volumen: 64 Número: 7
Páginas:
WOS Id: 000545775600048
ID de PubMed: 32312777
imagen Green Published

MÉTRICAS